Advertisement

Topics

Mylan to withdraw from Tel Aviv Stock Exchange

05:49 EST 13 Nov 2017 | Pharmafile

US drug maker Mylan has announced its intention to withdraw from the Tel Aviv Stock Exchange (TASE), ending its involvement for the first time since it entered it in November 2015.

The company was originally listed on the Exchange as part of a strategy to acquire Perrigo, a US-Israeli over-the-counter healthcare product manufacturer. The attempt ultimately fell through, with Mylan planning to remain on the Exchange. Now the company has U-turned on this and is due to be delisted on 12 February – just three months away.

read more

Original Article: Mylan to withdraw from Tel Aviv Stock Exchange

NEXT ARTICLE

More From BioPortfolio on "Mylan to withdraw from Tel Aviv Stock Exchange"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Healthcare
Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...